Nur Hafzan Md Hanafiah

Ms. Nur Hafzan Md Hanafiah

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
James Yau Hon Voo, MPharm(ClinPharm), BCPSJames Yau Hon Voo, MPharm(ClinPharm), BCPS
James Yau Hon Voo, MPharm(ClinPharm), BCPS
QLQi Ying Lean
Qi Ying Lean
Long MingLong Ming
Long Ming
NHNur Hafzan Md Hanafiah
Nur Hafzan Md Hanafiah
YAYaser Al-Worafi
Yaser Al-Worafi
BIBaharudin Ibrahim
Baharudin Ibrahim
Background: Incomplete childhood immunization against communicable diseases is a major concern and vaccine hesitancy remains a hurdle to overcome in primary vaccination programs. This study was to examine the parents’ vaccine knowledge, awareness and hesitancy in relation to their children’s immunization status. Methods: A cross-sectional questionnaire study design was used. The parents who brought their children for immunization visit or follow-up at four public health clinics located in Sandakan district were invited to participate in this survey. Informed consent was obtained before each participant completed a hard copy of self-administered questionnaire in either English or Malay versions. Results: Of 405 parents responded, they generally had good knowledge and awareness of vaccines, only a small percentage (6.8%) of parents were found vaccine hesitant. There were significant differences in vaccine knowledge and awareness in those from different education levels and employment status; similarly, these two factors also significantly affected the vaccine hesitancy among the parents. The parents’ knowledge score was found to be moderately associated with their awareness (r = 0.551, p < 0.01) and inversely correlated to vaccine hesitancy (r = −0.397, p < 0.01). Most of the children (n = 376, 92.8%) in the study were immunized. The children’s immunization status was significantly associated with the parents’ education level (p = 0.025). There was also a significant difference in the total vaccine knowledge scores between the groups of parents with different child immunization status (p = 0.05). Conclusion: This study revealed that parents with higher education had a better knowledge of vaccinations, were less vaccine hesitant and were more likely to ensure that their children complete the recommended course of immunization. It is crucial to ensure parents are well-informed about the safety and efficacy of vaccines so that the children are protected from communicable diseases by the child vaccination program.

30 June 2024 in Research in Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
HHHumayera Kabir Hana
Humayera Kabir Hana
SSSania Siddiqui
Sania Siddiqui
SGSiti Maisharah Sheikh Ghadzi
Siti Maisharah Sheikh Ghadzi
IAIrfhan Ali Hyder Ali
Irfhan Ali Hyder Ali
SOSiew Chin Ong
Siew Chin Ong
SHSabariah Noor Harun
Sabariah Noor Harun
Humayera Kabir Hana, Sania Siddiqui, Siti Maisharah Sheikh Ghadzi, Irfhan Ali Hyder Ali, Siew Chin Ong, Nur Hafzan Md Hanafiah, Sabariah Noor Harun. R Clin Pharm 2024;2:18-26. https://doi.org/10.59931/rcp.24.0003

1 January 2026 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
MMMarvi Metlo
Marvi Metlo
SOSiew Chin Ong
Siew Chin Ong
ATAi Lian Tan
Ai Lian Tan
DNDzul Azri Mohamed Noor
Dzul Azri Mohamed Noor
NHNur Hafzan Md Hanafiah
Nur Hafzan Md Hanafiah
Mustapha MohammedMustapha Mohammed
Mustapha Mohammed
Background: Renal cell carcinoma (RCC) treatment has evolved substantially with the introduction of targeted therapies. Pazopanib (PZP), an oral multikinase inhibitor, is approved for the first‐line treatment of advanced/metastatic RCC and has demonstrated clinical efficacy in prolonging progression‐free survival (PFS) and overall survival (OS). Compared to other targeted agents, PZP is associated with a more favorable safety profile. However, its real‐world performance and clinical utility across diverse populations, particularly in comparison with existing therapies, remain insufficiently explored. Methods: This systematic review adhered to PRISMA principles to assess publications published from 2010 to 2023. A thorough literature review was performed using Google Scholar, ScienceDirect, PubMed, Medline, Cochrane, and Scopus databases. The studies evaluated PZP’s PFS, OS, and safety profile. Results: PZP improved PFS compared to placebo, with a median PFS of 9.2 months versus 4.2 months. Compared to sunitinib, PZP had comparable efficacy (PFS: 8.4 vs. 9.5 months) but demonstrated fewer severe AEs. PZP demonstrated an OS of 22.9 months compared to 20.5 months for placebo. Grade 3/4 AEs were reported in 33% of PZP‐treated patients. Common toxicities included hypertension and diarrhea (each 4%), and serious cardiovascular events were observed in 3% of patients, which is less than other treatments. Elevations in liver enzymes alanine aminotransferase/aspartate aminotransferase (ALT/AST) were among the most frequent laboratory abnormalities. Compared to sunitinib, PZP had lower rates of hematological toxicities such as neutropenia and thrombocytopenia. Conclusion: PZP offers substantial benefits in PFS compared to placebo, with tolerable safety profiles. While its efficacy relative to sunitinib is similar, PZP’s lower hematologic toxicity profile may provide an advantage for specific patient populations. PZP can be considered a viable treatment option for RCC with manageable side effects. However, continued evaluation of its long‐term safety and real‐world outcomes is warranted to guide patient selection and optimize treatment strategies.

5 March 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSaba Javed
Saba Javed
UJUmar Javed
Umar Javed
DNDzul Azri Mohamed Noor
Dzul Azri Mohamed Noor
NHNur Hafzan Md Hanafiah
Nur Hafzan Md Hanafiah
TMTanveer Mustafa
Tanveer Mustafa
SHSabariah Noor Harun
Sabariah Noor Harun
Background: Most existing studies have predominantly examined the impact of single blood glucose measurements without considering how fluctuations over time may influence clinical outcomes. Moreover, no studies have yet explored the effect of blood glucose trajectories on pathological responses in breast cancer patients undergoing neo-adjuvant chemotherapy (NACT), highlighting a significant gap in the current literature. Purpose: To determine the impact of dynamic changes in blood glucose during neo-adjuvant chemotherapy on the pathological responses in women with breast cancer, with and without concomitant diabetes. Method: This prospective cohort study was conducted among women with locally advanced breast cancer receiving treatment at GINUM Hospital in Gujranwala, Pakistan. Data for the prospective phase were collected from 20 January 2023 to–13 May 2024. Clinical data were obtained using a structured data collection form. Diabetes status was confirmed at baseline using Glycated hemoglobin (HbA1c) and Fasting blood glucose (FBG) tests. Patients were classified into glycemic trajectories based on the values of their FBG values during the treatment period. Results: Five blood glucose trajectories were identified from the start of breast cancer treatment to the post-treatment period: normal glycemic trajectory (23 patients, 4.1%), erratic glycemic trajectory (130 patients, 23.2%), consistently hyperglycemic trajectory (127 patients, 22.7%), controlled diabetes (130 patients, 23.2%), and uncontrolled diabetes (150 patients, 26.8%). All glycemic trajectory groups demonstrated a non-significant increase in the odds of achieving Pathological partial response (pPR). Similar to pPR, the various categories of blood glucose trajectories were associated with a non-significant increase in the odds of Pathological no response (pNR). Among nondiabetic patients the group I(normal) and group III (consistently hyperglycemic) trajectories showed no significant interaction with pathological responses, as indicated by repeated measures ANOVA. Conclusion: Our findings indicated that fluctuations in FBG levels among individuals with diabetes were not associated with pathological responses to neo-adjuvant chemotherapy. This suggests that the rise in blood glucose levels in diabetic patients are more likely driven by their pre-existing metabolic dysfunction rather than their chemotherapy related pathological responses.